Sino Biopharmaceutical (Sino Biopharmaceutical) Change In Receivables : $0 Mil (TTM As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Change In Receivables?

Sino Biopharmaceutical's change in receivables for the quarter that ended in Jun. 2023 was $0 Mil. It means Sino Biopharmaceutical's Accounts Receivable stayed the same from Dec. 2022 to Jun. 2023 .

Sino Biopharmaceutical's change in receivables for the fiscal year that ended in Dec. 2022 was $-67 Mil. It means Sino Biopharmaceutical's Accounts Receivable increased by $67 Mil from Dec. 2021 to Dec. 2022 .

Sino Biopharmaceutical's Accounts Receivable for the quarter that ended in Jun. 2023 was $993 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sino Biopharmaceutical's Days Sales Outstanding for the six months ended in Jun. 2023 was 84.92.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sino Biopharmaceutical's liquidation value for the six months ended in Jun. 2023 was $-1,000 Mil.

Sino Biopharmaceutical Change In Receivables Historical Data

The historical data trend for Sino Biopharmaceutical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Change In Receivables Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

27.99

-22.97

-253.60

-67.42

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Sino Biopharmaceutical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0 Mil.

Sino Biopharmaceutical (OTCPK:SBMFF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sino Biopharmaceutical's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	992.679	/	2133.247	*	91
=	84.92

2. In Ben Graham's calculation of liquidation value, Sino Biopharmaceutical's accounts receivable are only considered to be worth 75% of book value:

Sino Biopharmaceutical's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2189.013	-	4074.913	+	0.75 * 992.679	+	0.5 * 281.858
=	-1,000

Sino Biopharmaceutical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SBHMY:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.